Benhealth Biopharma

Benhealth Biopharma is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to developing innovative small molecule drugs for metabolic diseases. The company's research and development efforts are primarily focused on metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity. Its lead program, BHT-210, is a potent and highly selective thyroid hormone receptor beta (THR-beta) agonist designed to reduce liver fat and inflammation. Benhealth's pipeline also includes candidates targeting the glucagon-like peptide 1 receptor (GLP-1R) and other metabolic pathways. Founded by industry veterans, the company aims to address the growing global burden of chronic metabolic disorders through precision medicine.